These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27252317)

  • 61. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Direct-acting antiviral agents for the treatment of HCV.
    Thompson AJ; Locarnini S
    Antivir Ther; 2012; 17(6 Pt B):1105-7. PubMed ID: 23188736
    [No Abstract]   [Full Text] [Related]  

  • 63. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
    Søholm J; Holm DK; Mössner B; Madsen LW; Hansen JF; Weis N; Sauer AP; Awad T; Christensen PB
    PLoS One; 2019; 14(7):e0220297. PubMed ID: 31348813
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of hepatitis C virus treatment between incarcerated and community patients.
    Rice JP; Burnett D; Tsotsis H; Lindstrom MJ; Cornett DD; Voermans P; Sawyer J; Striker R; Lucey MR
    Hepatology; 2012 Oct; 56(4):1252-60. PubMed ID: 22505121
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ANTIVIRAL TREATMENT OF HEPATITIS C IN SERBIAN PRISON SETTING: MEDICAL TREATMENT OUTCOMES AND PATIENTS' ADHERENCE.
    Simonović Babić J; Bojović K; Delić D; Katanić N; Mitrović N; Malinić J
    Med Pregl; 2016; 69(3-4):85-91. PubMed ID: 27506095
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Recommendations for the treatment of chronic genotype 1 hepatitis C virus infection].
    Silva MO; Ridruejo E; Galdame O; Bessone F; Colombato L; Daruich J; Fainboim H; Fassio E; Fay F; Frider B; Gadano A; Galoppo MC; González J; Tanno H; Terg R; Villamil F; ;
    Acta Gastroenterol Latinoam; 2012 Sep; 42(3):234-49. PubMed ID: 23214356
    [No Abstract]   [Full Text] [Related]  

  • 69. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.
    Assoumou SA; Tasillo A; Vellozzi C; Eftekhari Yazdi G; Wang J; Nolen S; Hagan L; Thompson W; Randall LM; Strick L; Salomon JA; Linas BP
    Clin Infect Dis; 2020 Mar; 70(7):1388-1396. PubMed ID: 31095676
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues".
    Sheehan Y; Grebely J; Lloyd AR
    J Hepatol; 2024 Mar; 80(3):e107-e108. PubMed ID: 37890725
    [No Abstract]   [Full Text] [Related]  

  • 71. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.
    Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C
    Addiction; 2021 May; 116(5):1162-1171. PubMed ID: 33006784
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
    Asselah T; Bourlière M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):859-70. PubMed ID: 26600224
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence and features of chronic viral hepatitis and HIV coinfection in Italian prisons.
    Stasi C; Silvestri C; Fanti E; Di Fiandra T; Voller F
    Eur J Intern Med; 2016 Oct; 34():e21-e22. PubMed ID: 27189044
    [No Abstract]   [Full Text] [Related]  

  • 76. Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015.
    Kivimets K; Uusküla A; Lazarus JV; Ott K
    BMC Infect Dis; 2018 Jul; 18(1):339. PubMed ID: 30031373
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Profiles and clinical management of hepatitis C patients in Spain: disHCovery study.
    Buti M; Franco A; Carmona I; Sánchez-Ruano JJ; Sansó A; Berenguer M; García-Buey L; Hernández-Guerra M; Morillas RM; Ledesma F; Esteban R;
    Rev Esp Quimioter; 2015 Jun; 28(3):145-53. PubMed ID: 26032999
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
    Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
    J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
    Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
    J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
    Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
    Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.